Toll样受体激动剂在疫苗研发中的研究进展  

Progress in Toll like receptor agonists as adjuvants in vaccine design

作　　者：王云鹏[1] 杨晓明 李玉华[1] 

机构地区：[1]中国食品药品检定研究院,北京100050 [2]国药集团中国生物技术股份有限公司,北京100029

出　　处：《中华微生物学和免疫学杂志》2017年第6期474-478,共5页Chinese Journal of Microbiology and Immunology

摘　　要：固有免疫细胞具有抗感染和疾病防御作用.这方面的核心是通过建立广泛的特异性联系,即通过固有免疫细胞表达模式识别受体（pattern recognition receptors,PRRs）来检测病原体相关模式和危险物相关模式.Toll样受体（TLR）是模式识别受体中研究的最为广泛的一种受体.因此,TLR的激活具有促进固有炎症因子的释放和诱导特异性免疫两种作用.充分利用TLR的特点,在疫苗设计中加入相应的TLR受体激动剂,可以加速疫苗的免疫应答,产生更持久的保护.Innate immune cells have a critical role in defense against infections and diseases.Central to this is the broad specificity with which they can detect pathogen-associated patterns and danger-associated patterns via the pattern recognition receptors （PRRs） they express.TLR is one of the most largely studied families of PRRs.Activation of TLR promotes both innate inflammatory responses and the induction of adaptive immunity.Given the characteristics of TLR,various Toll like receptor agonists are used in vaccine design to accelerate the immune response and produce long-lasting protection.

关 键 词：TOLL样受体 疫苗 佐剂 

分 类 号：R392[医药卫生—免疫学]